# US 2016/0355513 A1 · Compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355513 A1
- Document ID: US20160355513A1
- Status: Published application
- Kind: A1
- Application number: 15/241,773
- Filed: 2016-08-19
- Published: 2016-12-08
- Earliest claimed: 2009-04-03
- Assignees: Plexxikon Inc.; Hoffman-La Roche Inc.
- Applicants: Plexxikon Inc.; Hoffman-La Roche Inc.
- Inventors: Dipen Desai; Ralph Diodone; Zenaida Go; Prabha N. Ibrahim; Raman Iyer; Hans-Juergen Mair; Harpreet K. Sandhu; Navnit H. Shah; Gary Visor; Nicole Wyttenbach; Stephan Lauper; Johannes Pudewell; Frank Wierschem
- Web page: https://patentgrep.com/patent/US20160355513A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 9/10: Dispersions; Emulsions
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- F01N 13/08: Other arrangements or adaptations of exhaust conduits {(pipes, joints or supports therefor in general F16L; collecting or removing exhaust gases of vehicle engines in workshops B08B15/00, on highways E01C1/005)}
- F01N 13/1877: {the channels or tubes thereof being made integrally with the housing}
- F01N 13/1888: {the housing of the assembly consisting of two or more parts, e.g. two half-shells}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- F01N 2470/06: Tubes being formed by assembly of stamped or otherwise deformed sheet-metal
- F01N 2470/14: Plurality of outlet tubes, e.g. in parallel or with different length
- F01N 2470/16: Plurality of inlet tubes, e.g. discharging into different chambers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- F01N: GAS-FLOW SILENCERS OR EXHAUST APPARATUS FOR MACHINES OR ENGINES IN GENERAL; GAS-FLOW SILENCERS OR EXHAUST APPARATUS FOR INTERNAL-COMBUSTION ENGINES (arrangements in connection with gas exhaust of propulsion units in vehicles B60K13/00; combustion-air intake silencers specially adapted for, or arranged on, internal-combustion engines F02M35/00; protecting against, or damping, noise in general G10K11/16)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.

## Claims

### Claim 1

A crystalline polymorph Form 1 of Compound I:
that exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 11.0, 12.5, and 15.4 degrees 2θ.

### Claim 2 (depends on 1)

A crystalline polymorph according to claim 1, wherein said polymorph exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 18.6, and 22.2 degrees 2θ.

### Claim 3 (depends on 1)

A crystalline polymorph according to claim 1, wherein said polymorph exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 16.1, 18.6, 19.0, 22.2 and 26.8 degrees 2θ.

### Claim 4 (depends on 1)

A crystalline polymorph according to claim 1, wherein said polymorph exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern of FIG. 1.

### Claim 5 (depends on 1)

A purified form of the crystalline polymorph of claim 1.
